{"id":1502,"date":"2026-03-03T15:15:17","date_gmt":"2026-03-03T15:15:17","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/03\/fenebrutinib-again-bests-aubagio-in-trial-at-cutting-ms-relapse-rates\/"},"modified":"2026-03-03T15:15:17","modified_gmt":"2026-03-03T15:15:17","slug":"fenebrutinib-again-bests-aubagio-in-trial-at-cutting-ms-relapse-rates","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/03\/03\/fenebrutinib-again-bests-aubagio-in-trial-at-cutting-ms-relapse-rates\/","title":{"rendered":"Fenebrutinib again bests Aubagio in trial at cutting MS relapse rates"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/03\/03\/fenebrutinib-again-bests-aubagio-reducing-ms-relapse-rates-clinical-trial\/\" title=\"Fenebrutinib again bests Aubagio in trial at cutting MS relapse rates\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"553\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2026\/03\/iStock-801335908-800x553.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A smiling woman holds up a card with the words &quot;clinical trial&quot; printed on it in large green capital letters.\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"160015\" \/><\/a><\/p>\n<p>Fenebrutinib, Genentech&#8217;s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023), were announced late last year. Now, Genentech has reported that [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/03\/03\/fenebrutinib-again-bests-aubagio-reducing-ms-relapse-rates-clinical-trial\/\">Fenebrutinib again bests Aubagio in trial at cutting MS relapse rates<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/03\/03\/fenebrutinib-again-bests-aubagio-reducing-ms-relapse-rates-clinical-trial\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fenebrutinib, Genentech&#8217;s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023), were announced late last year. Now, Genentech has reported that&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1503,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1502","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1502"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1502\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/1503"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}